Press Releases
EndoGastric® Solutions Expands Commercial Leadership Team to Meet Increased Demand for TIF® Procedure for Reflux
EndoGastric Solutions®, Inc. (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today the addition of two senior executives to its leadership team: Martin Reid, Vice President of Sales, and Ted Stephens, Vice President of Marketing and Professional Education.
EndoGastric Solutions Launches EsophyX® Z Technology for the TIF® 2.0 Procedure in Europe
Early Access Program starts in Italy with CE-marked device to meet reflux treatment demand REDMOND, Wash. – EndoGastric Solutions®, Inc. (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that the...
EndoGastric Solutions to Host Product Theater Session on the TIF® Procedure at Digestive Disease Week® (DDW) 2017
Plus, ASGE Special Interest Group meeting to also highlight Endoluminal Therapy for GERD EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that the company will host an educational...
SAGES Clinical Spotlight Review Gives “Strong Recommendation” to EsophyX® device used in TIF® 2.0 Procedure
SAGES Board of Governors reviewed and approved statement REDMOND, Washington – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), is pleased to announce that based on clinical evidence, the Board of...
Medicare Patients in North Carolina, South Carolina, West Virginia and Virginia Now Have a New Minimally Invasive Treatment Option for Reflux Disease
EndoGastric Solutions® Provides Access to the TIF 2.0 procedure through Medicare Administrative Contractor Palmetto GBA REDMOND, Washington – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), is...
EndoGastric Solutions Announces Publication of Long-Term Data Demonstrating TIF® 2.0 Procedure Offers Durable Treatment of Chronic GERD
Three-year follow up data from the TEMPO randomized controlled trial supports evidence of TIF procedure as an effective, long-term treatment option for GERD REDMOND, Washington – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for...
EGS Receives Positive Medical Coverage Policy by HCSC for TIF Procedure with EsophyX Device
Newly Issued Technology Coverage Statement on Minimally Invasive Surgical Options for GERD REDMOND, Washington. – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that Health Care...
American Gastroenterological Association Releases Technology Coverage Statement on Minimally Invasive Surgical Options for GERD
REDMOND, Washington. – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that the American Gastroenterological Association (AGA) has issued a Technology Coverage Statement on Minimally...
EndoGastric Solutions Announces First Use and Limited Market Release of Next-Generation Version of EsophyX® Device
Latest EsophyX® Z Fastener Delivery System Significantly Reduces the Number of Steps in the TIF® (Transoral Incisionless Fundoplication) Procedure REDMOND, Washington – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal...